Global Liquid Biopsy Market - Growth Drivers, Opportunities and Forecast Analysis to 2025
Summary -
A new market
study, titled “Global Liquid Biopsy Market - Growth Drivers,
Opportunities and Forecast Analysis to 2025” has been featured on WiseGuyReports.
According
to RNCOS’ new research report “Global Liquid Biopsy Market Outlook to 2023”,
the global liquid biopsy market is projected to cross the US$ 5 Billion mark by
the end of 2023. A number of factors such as growing public and private funding
to support research activities in the field of liquid biopsy, rising preference
by oncologists for liquid biopsy, growing number of product launches to support
development and increasing adoption of personalised medicine is driving the
growth of this market.
In this
report, a major focus has been on the development of innovative products based
on different application, technology and different sample types. In this
context, the study provides present and future outlooks for the two broad
categories of liquid biopsy market; by analyte and by sample type. The former
comprises of the three marker categories that dominate liquid biopsy today:
circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and
extracellular vesicles (or exosomes). On the other hand, the latter includes
the two major bodily fluid samples: blood and urine. According to report, blood
is the most widely used sample type and is expected to remain the largest
market based on sample type in the coming years as well.
The report
also includes a detailed analysis of commercialized liquid biopsy products. A handful
of companies are currently marketing liquid biopsies, but commercial
applications remain largely limited to therapy selection, and treatment
monitoring. A detailed pipeline analysis of upcoming liquid biopsy products has
also been conducted. Most of the current research is focused on utilizing
liquid biopsy for diagnostic purposes such as response evaluation, expression
profiling, tumor diagnosis, and treatment monitoring in a blood test.
The market
has been divided into four major geographic regions: North America, Europe,
Asia, and Rest of the World. North America is the largest market for the liquid
biopsy industry. This high share is attributed to the relatively high adoption
rate of liquid biopsy coupled with launch of new and advanced products in the
market. The Asian market is poised to witness the highest growth owing to
increasing focus of players in this region.
RNCOS, in
its report, further covers how major trends and drivers, mainly therapy
selection, increasing use of circulating tumor cells for cancer screening,
growing interest of venture capital firms etc., will propel the industry’s
growth. An analysis has also been done of a few factors limiting the growth of
the industry.
After an
exhaustive study of the industry, RNCOS has laid out the primary market players
that are engaged in providing liquid biopsy–based tools and services. These
players are working over a vast variety of products such as blood-based tests,
urine-based tests, assays and instruments for sample extraction, amplification
and purification, and constantly upgrading their portfolio to keep up with the
latest developments in the field. Some of these players include QIAGEN NV,
Roche Diagnostics, Foundation Medicine, Trovagene, Guardant Health, and
Biocept.
Overall,
even though the market is in its nascent stage at the moment, it is expanding
at an almost exponential rate. With new players entering the market, increase
in the number of collaborations and strong support from research institutes,
the liquid biopsy market is bound to witness rampant diversification and growth
in the coming years.
FOR MORE
DETAILS: https://www.wiseguyreports.com/reports/2769071-global-liquid-biopsy-market-outlook-to-2023
About Us:
Wise Guy Reports is part of the Wise Guy Research
Consultants Pvt. Ltd. and offers premium progressive statistical surveying,
market research reports, analysis & forecast data for industries and
governments around the globe.
Contact Us:
NORAH
TRENT
Ph: +162-825-80070
(US)
Ph: +44 2035002763
(UK)
Comments
Post a Comment